共查询到20条相似文献,搜索用时 187 毫秒
1.
Uzuner H Bauer R Fan TP Guo DA Dias A El-Nezami H Efferth T Williamson EM Heinrich M Robinson N Hylands PJ Hendry BM Cheng YC Xu Q 《Journal of ethnopharmacology》2012,140(3):458-468
Background and aims
GP-TCM is the 1st EU-funded Coordination Action consortium dedicated to traditional Chinese medicine (TCM) research. This paper aims to summarise the objectives, structure and activities of the consortium and introduces the position of the consortium regarding good practice, priorities, challenges and opportunities in TCM research. Serving as the introductory paper for the GP-TCM Journal of Ethnopharmacology special issue, this paper describes the roadmap of this special issue and reports how the main outputs of the ten GP-TCM work packages are integrated, and have led to consortium-wide conclusions.Materials and methods
Literature studies, opinion polls and discussions among consortium members and stakeholders.Results
By January 2012, through 3 years of team building, the GP-TCM consortium had grown into a large collaborative network involving ∼200 scientists from 24 countries and 107 institutions. Consortium members had worked closely to address good practice issues related to various aspects of Chinese herbal medicine (CHM) and acupuncture research, the focus of this Journal of Ethnopharmacology special issue, leading to state-of-the-art reports, guidelines and consensus on the application of omics technologies in TCM research. In addition, through an online survey open to GP-TCM members and non-members, we polled opinions on grand priorities, challenges and opportunities in TCM research. Based on the poll, although consortium members and non-members had diverse opinions on the major challenges in the field, both groups agreed that high-quality efficacy/effectiveness and mechanistic studies are grand priorities and that the TCM legacy in general and its management of chronic diseases in particular represent grand opportunities. Consortium members cast their votes of confidence in omics and systems biology approaches to TCM research and believed that quality and pharmacovigilance of TCM products are not only grand priorities, but also grand challenges. Non-members, however, gave priority to integrative medicine, concerned on the impact of regulation of TCM practitioners and emphasised intersectoral collaborations in funding TCM research, especially clinical trials.Conclusions
The GP-TCM consortium made great efforts to address some fundamental issues in TCM research, including developing guidelines, as well as identifying priorities, challenges and opportunities. These consortium guidelines and consensus will need dissemination, validation and further development through continued interregional, interdisciplinary and intersectoral collaborations. To promote this, a new consortium, known as the GP-TCM Research Association, is being established to succeed the 3-year fixed term FP7 GP-TCM consortium and will be officially launched at the Final GP-TCM Congress in Leiden, the Netherlands, in April 2012. 相似文献2.
Chan K Shaw D Simmonds MS Leon CJ Xu Q Lu A Sutherland I Ignatova S Zhu YP Verpoorte R Williamson EM Duez P 《Journal of ethnopharmacology》2012,140(3):469-475
Ethnopharmacological relevance
Studies on traditional Chinese medicine (TCM), like those of other systems of traditional medicine (TM), are very variable in their quality, content and focus, resulting in issues around their acceptability to the global scientific community. In an attempt to address these issues, an European Union funded FP7 consortium, composed of both Chinese and European scientists and named “Good practice in traditional Chinese medicine” (GP-TCM), has devised a series of guidelines and technical notes to facilitate good practice in collecting, assessing and publishing TCM literature as well as highlighting the scope of information that should be in future publications on TMs. This paper summarises these guidelines, together with what has been learned through GP-TCM collaborations, focusing on some common problems and proposing solutions. The recommendations also provide a template for the evaluation of other types of traditional medicine such as Ayurveda, Kampo and Unani.Materials and methods
GP-TCM provided a means by which experts in different areas relating to TCM were able to collaborate in forming a literature review good practice panel which operated through e-mail exchanges, teleconferences and focused discussions at annual meetings. The panel involved coordinators and representatives of each GP-TCM work package (WP) with the latter managing the testing and refining of such guidelines within the context of their respective WPs and providing feedback.Results
A Good Practice Handbook for Scientific Publications on TCM was drafted during the three years of the consortium, showing the value of such networks. A “deliverable – central questions – labour division” model had been established to guide the literature evaluation studies of each WP. The model investigated various scoring systems and their ability to provide consistent and reliable semi-quantitative assessments of the literature, notably in respect of the botanical ingredients involved and the scientific quality of the work described. This resulted in the compilation of (i) a robust scoring system and (ii) a set of minimum standards for publishing in the herbal medicines field, based on an analysis of the main problems identified in published TCM literature.Conclusion
Good quality, peer-reviewed literature is crucial in maintaining the integrity and the reputation of the herbal scientific community and promoting good research in TCM. These guidelines provide a clear starting point for this important endeavour. They also provide a platform for adaptation, as appropriate, to other systems of traditional medicine. 相似文献3.
Ellie J.Y. Kim Yuling Chen Johnson Q. Huang Kong M. Li Valentina Razmovski-Naumovski Josiah Poon Kelvin Chan Basil D. Roufogalis Andrew J. McLachlan Sui-Lin Mo Depo Yang Meicun Yao Zhaolan Liu Jianping Liu George Q. Li 《Journal of ethnopharmacology》2013
Ethnopharmacological relevance
While there is an increasing number of toxicity report cases and toxicological studies on Chinese herbal medicines, the guidelines for toxicity evaluation and scheduling of Chinese herbal medicines are lacking.Aim
The aim of this study was to review the current literature on potentially toxic Chinese herbal medicines, and to develop a scheduling platform which will inform an evidence-based regulatory framework for these medicines in the community.Materials and methods
The Australian and Chinese regulations were used as a starting point to compile a list of potentially toxic herbs. Systematic literature searches of botanical and pharmaceutical Latin name, English and Chinese names and suspected toxic chemicals were conducted on Medline, PubMed and Chinese CNKI databases.Results
Seventy-four Chinese herbal medicines were identified and five of them were selected for detailed study. Preclinical and clinical data were summarised at six levels. Based on the evaluation criteria, which included risk–benefit analysis, severity of toxic effects and clinical and preclinical data, four regulatory classes were proposed: Prohibited for medicinal usage, which are those with high toxicity and can lead to injury or death, e.g., aristolochia; Restricted for medicinal usage, e.g., aconite, asarum, and ephedra; Required warning label, e.g., coltsfoot; and Over-the-counter herbs for those herbs with a safe toxicity profile.Conclusion
Chinese herbal medicines should be scheduled based on a set of evaluation criteria, to ensure their safe use and to satisfy the need for access to the herbs. The current Chinese and Australian regulation of Chinese herbal medicines should be updated to restrict the access of some potentially toxic herbs to Chinese medicine practitioners who are qualified through registration. 相似文献4.
欧盟在全球植物药市场的地位举足轻重,推动更多中成药尤其是复方产品进入欧盟药品市场,对中药国际化具有重要战略意义。立足中成药欧盟市场准入中的注册评价技术标准这一关键环节,从欧盟相关法律法规基础与技术标准体系构成,以及产品质量、安全与有效性评价技术要求等方面,系统剖析欧盟草药药品注册评价技术标准特点,并针对欧盟复方产品的要求进行专门讨论。研究结果对于我国深入认识欧盟草药药品监管体系内涵、搭建中欧植物药科学监管机制研究的“桥梁”具有良好学术价值,对指导和推动中成药开展欧盟药品注册工作具有积极地促进作用。 相似文献
5.
对药品实行注册管理制度是确保公众健康的全球通用的监管措施。中药作为承载中医药理论与用药实践的主要载体,对中药产品的注册管理又具有其特殊性。2017年正式实施的《中医药法》提出了建立符合中医药特点管理制度的发展方针,研究制定配套文件或修订现行规章以适应衔接其立法精神是当前重要的现实问题之一。欧盟在植物药监管领域取得了良好成效,本文旨在系统分析欧盟对其注册管理的法规体系,深入剖析其监管特点和对中国中药注册管理的启示,以期为当前《中医药法》背景下中药监管制度的改革提供参考。 相似文献
6.
欧盟是全球最重要的区域一体化组织,也是西方最成熟的植物药市场,2004年《欧盟传统草药指令》(2004/24/EC)的颁布标志着欧盟草药药品注册管理制度的成熟和完善,不仅对统一监管草药具有里程碑式意义,而且为中药国际化发展提供了重要机遇。2004/24/EC法令颁布至今已有17年,已批准2000余件草药药品上市申请,而我国仅有极少数中药产品成功在欧盟成员国获批,中药欧盟注册仍然任重道远。旨在系统分析欧盟草药药品注册管理制度及其实施有关数据情况,并探索未来中药欧盟注册的思路与策略,以期为有关企业及政府部门提供参考。 相似文献
7.
Systems approaches and polypharmacology for drug discovery from herbal medicines: An example using licorice 总被引:1,自引:0,他引:1
Ethnopharmacological relevance
Licorice, one of the oldest and most popular herbal medicines in the world, has been widely used in traditional Chinese medicine as a cough reliever, anti-inflammatory, anti-anabrosis, immunomodulatory, anti-platelet, antiviral (hepatitis) and detoxifying agent. Licorice was used as an example to show drug discovery from herbal drugs using systems approaches and polypharmacology.Aim of the study
Herbal medicines are becoming more mainstream in clinical practice and show value in treating and preventing diseases. However, due to its extreme complexity both in chemical components and mechanisms of action, deep understanding of botanical drugs is still difficult. Thus, a comprehensive systems approach which could identify active ingredients and their targets in the crude drugs and more importantly, understand the biological basis for the pharmacological properties of herbal medicines is necessary.Materials and methods
In this study, a novel systems pharmacology model that integrates oral bioavailability screening, drug-likeness evaluation, blood–brain barrier permeation, target identification and network analysis has been established to investigate the herbal medicines.Results
The comprehensive systems approach effectively identified 73 bioactive components from licorice and 91 potential targets for this medicinal herb. These 91 targets are closely associated with a series of diseases of respiratory system, cardiovascular system, and gastrointestinal system, etc. These targets are further mapped to drug–target and drug–target–disease networks to elucidate the mechanism of this herbal medicine.Conclusion
This work provides a novel in silico strategy for investigation of the botanical drugs containing a huge number of components, which has been demonstrated by the well-studied licorice case. This attempt should be helpful for understanding definite mechanisms of action for herbal medicines and discovery of new drugs from plants. 相似文献8.
Background
Value chain analyses are commonly used to understand socioeconomic and power relationships in the production chain from the initial starting material to a final (generally high value) product. These analyses help in terms of understanding economic processes but also have been used in the context of socioeconomic and socioecological research.Aims of the study
However, there is a gap in the ethnopharmacological literature in terms of understanding what relevance a critical analysis of value chains of herbal medicines could have. Here we provide a research framework for achieving such an analysis.Methods
An extensive review of the literature available on value chains and their analysis was conducted, based both on a systematic online search of the relevant literature and a hand search of bibliographies and discussions with experts in value chain analysisResults
While the concept of value chains is commonly used in the relevant industries, very few studies investigate the value chains of herbal medicines and products derived from them. The studies identified mostly look at socio-ecological aspects, especially in the context of sustainable resource use. We suggest an analytical framework which can help in understanding value chains in the context of ethnopharmacology and can serve as a basis for addressing questions related to value chains and their relevance in ethnopharmacology.Conclusions
We identified a crucial gap in current ethnopharmacological and medicinal plant research which impacts on a wide-range of factors relevant for a sustainable, socio-culturally equitable and safe supply of herbal medicines. 相似文献9.
欧盟是中药国际化的桥梁,中药在欧盟成功注册具有重要的战略意义。该文简要回顾了10年来欧盟植物药政策的进展以及品种的批准情况,系统研究了欧盟植物药注册的政策法规,分析了一些中药欧盟注册的典型案例,重点从注册类别、审批程序、审批部门、申报品种、申报企业5个方面分析影响注册成败的关键因素,并提出了突破欧盟注册障碍的相应对策与建议,以期为我国中药在欧盟成功注册和实施中药国际化战略提供参考和借鉴。 相似文献
10.
11.
Flower A Witt C Liu JP Ulrich-Merzenich G Yu H Lewith G 《Journal of ethnopharmacology》2012,140(3):550-554
Ethnographic relevance
Clinical trials investigating Chinese herbal medicine (CHM) have been frequently criticised for their lack of scientific rigour. As part of the GP-TCM project a team of experienced clinical researchers and CHM practitioners have developed clinical trial guidelines for CHM that combine an appreciation for traditional methods of practice with detailed and practical advice on research methodology.Materials and methods
This paper presents an executive summary of this work. It introduces the practice of CHM and the key considerations that need to be addressed whilst researching this traditional medical system.Results
These guidelines emphasise the importance of identifying best practice, and then developing and applying appropriate and rigorous research methodologies to investigate CHM as a whole system.Conclusions
It is hoped that this will encourage a thoughtful and meticulous process of investigation that will clarify the contribution that CHM can make to our future healthcare. Innovative new approaches are considered including the application of the new “omic” technologies and systems biology as a way of enhancing our understanding of traditional practice 相似文献12.
Zhang L Yan J Liu X Ye Z Yang X Meyboom R Chan K Shaw D Duez P 《Journal of ethnopharmacology》2012,140(3):519-525
Ethnopharmacological relevance
Traditional Chinese Medicine (TCM), including Traditional Chinese Medicine drugs (TCM drugs), has been playing a very important role in health protection and disease control for thousands of years in China. Relying on natural products, mainly of herbal origin, used either as raw materials for decoction, as prepared herbal medicines or as formulated traditional medicines, TCM is still widely accepted by Chinese people, especially for chronic diseases treatment. This extensive use warrants safety measures and so TCM drug safety monitoring and risk management are becoming increasingly important tasks for the Chinese State Food and Drug Administration (SFDA).Methods
The Adverse Drug Reaction (ADR) monitoring system in China was established both for western and TCM drugs in 1989 as a voluntary reporting system with a National Center collecting and compiling reports. Serious or multi-case reports on individual TCM drug or formulated products are detailed in the Chinese ADR Information Bulletin to inform the public and Drug Administrative authorities for risk management.Results
About 10–15% of the ADR reports received by the National Center are related to TCM drugs and mainly pertaining to the formulated products. In certain cases, the suspension of a particular TCM preparation is decided by SFDA China.Conclusion
The model of safety monitoring and risk management of TCM drugs is still under exploration. Indeed, the characteristics and risk factors associated with these drugs require both proper understanding and control of the risk by strengthening standardization of clinical applications, basic science research, quality control in manufacturing, exploration of the actives monitoring methodology and enhancement of international communication and cooperation. 相似文献13.
Current Status and Future Perspective in the Globalization Of Traditional Chinese Medicines
下载免费PDF全文
![点击此处可从《World Journal of Traditional Chinese Medicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Wan-Ying Wu Wen-Zhi Yang Jin-Jun Hou De-An Guo 《World Journal of Traditional Chinese Medicine》2015,(1)
Globalization of traditional Chinese medicines started around the 1996, which was initiated by the Chinese government. However, some substantial progress was only achieved in recent years including the adoption of TCM quality monographs in the western pharmacopoeias (United States Pharmacopoeia and European Pharmacopoeia) and registration in main stream drug regulatory agencies such as US Food and Drug Administration (FDA) and European Medicines Agency (EMA). So far, several TCM herbal quality monographs were adopted by the United States Pharmacopoeia including China Salvia, Ganoderma lucidum and Panax notoginseng, etc. Over 45 TCM quality monographs were recorded in the European Pharmacopoeia with 20 more in the progress. After the successful registration of the first TCM product named Di Ao Xin Xue Kang as traditional medicine in Medicines Evaluation Board of the Netherlands, several other TCM herbal products are in the registration process in several European member states. So far, there has been still no any TCM product registered as a drug in FDA despite of a few products in phase III or phase II clinical trials. This review summarized the progress made in the globalization of traditional Chinese medicines in the recent years and the future issues in this regard were also projected. 相似文献
14.
15.
Prescription pattern of Chinese herbal products for hypertension in Taiwan: A population-based study
Ethnopharmacological relevance
Traditional Chinese medicine (TCM) has been commonly used in Asia country. The aim of this study is to analyze the utilization of TCM among hypertensive patients in Taiwan.Materials and methods
The use of TCM for primary hypertensive patients was evaluated using a randomly sampled cohort of 1,000,0s recruited from the National Health Insurance Research Database in 5-year period from 2006 to 2010.Results
Overall, 49.7% (n=42,586) of primary hypertension utilized TCM and 12.1% (n=5132) of them used TCM for the treatment of hypertension. Among the top 10 most frequently prescribed herbal formulae, Tian-Ma-Gou-Teng-Yin, Gout-Teng-San, Liu-Wei-Di-Huang-Wang and its derivatives were found to be the most common herbal formulae prescribed by TCM doctors for the treatment of hypertension in Taiwan.Conclusion
This study showed the utilization pattern of Chinese herbal product in patients with hypertension. Further researches and clinical trials are needed to evaluate the efficacy of these Chinese formulae or its ingredients in treating hypertension. 相似文献16.
17.
18.
19.
Anthony Booker Debora Frommenwiler Deborah Johnston Chinenye Umealajekwu Eike Reich Michael Heinrich 《Journal of ethnopharmacology》2014
Ethnopharmacological relevance
Herbal medicine value chains have generally been overlooked compared with food commodities. Not surprisingly, revenue generation tends to be weighted towards the end of the chain and consequently the farmers and producers are the lowest paid beneficiaries. Value chains have an impact both on the livelihood of producers and on the composition and quality of products commonly sold locally and globally and consequently on the consumers. In order to understand the impact of value chains on the composition of products, we studied the production conditions for turmeric (Curcuma longa) and the metabolomic composition of products derived from it. We aimed at integrating these two components in order to gain a better understanding of the effect of different value chains on the livelihoods of some producers.Materials and methods
This interdisciplinary project uses a mixed methods approach. Case studies were undertaken on two separate sites in India. Data was initially gathered on herbal medicine value chains by means of semi-structured interviews and non-participant observations. Samples were collected from locations in India, Europe and the USA and analysed using 1H NMR spectroscopy coupled with multivariate analysis software and with high performance thin layer chromatography (HPTLC).Results
We investigate medicinal plant value chains and interpret the impact different value chains have on some aspects of the livelihoods of producers in India and, for the first time, analytically assess the chemical variability and quality implications that different value chains may have on the products available to end users in Europe. There are benefits to farmers that belonged to an integrated chain and the resulting products were subject to a higher standard of processing and storage.By using analytical methods, including HPTLC and 1H NMR spectroscopy, it has been possible to correlate some variations in product composition for selected producers and identify strengths and weaknesses of some types of value chains. The two analytical techniques provide different and complementary data and together they can be used to effectively differentiate between a wide variety of crude drug powders and herbal medicinal products.Conclusions
This project demonstrates that there is a need to study the links between producers and consumers of commodities produced in so-called ‘provider countries’ and that metabolomics offer a novel way of assessing the chemical variability along a value chain. This also has implications for understanding the impact this has on the livelihood of those along the value chain. 相似文献20.